Xenon contrast agent ( DrugBank: Xenon )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 22 | Moyamoya disease | 1 |
22. Moyamoya disease
Clinical trials : 14 / Drugs : 21 - (DrugBank : 14) / Drug target genes : 28 - Drug target pathways : 44
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01419275 (ClinicalTrials.gov) | April 2009 | 16/8/2011 | Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients | Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients | Cerebrovascular Accident;Moyamoya Disease | Drug: Xenon contrast agent;Device: Magnetic Resonance Imaging | Stanford University | NULL | Completed | N/A | N/A | All | 126 | N/A | United States |